Aspects of diet, including macronutrient and food proﬁles, may affect visceral fat mass and metabolic syndrome.
"Aspects of diet, including macronutrient and food proﬁles, may affect visceral fat mass and metabolic syndrome. Previous studies exploring the effects of high-fat diets often include E-dense diets with large amounts of processed carbohydrates and poor overall quality, confounding effects of a high fat intake per se Aim: to test the hypothesis that consuming energy primarily from carbohydrate or fat in diets with similar food proﬁles would differentially affect the ability to reverse visceral adiposity and metabolic syndrome"
"Primary: visceral adiposity and metabolic syndrome markers Visceral adiposity and other measures of body composition, including: - weight - BMI - waist size - body fat %, body fat mass - subcutaneous fat Measure of metabolic syndrome: - SBP, DBP - lipids - glucose control (FBG, HbA1c) - inflammation (HOMA)"
"Both diets similarly improved (WG SS, BG NSS): - weight - waist size - abdominal subcutaneous fat mass - visceral fat mass - liver fat and liver function markers - TG - fasting insulin - insulin C-peptide - HbA1c - HOMA Diets differed (BG SS) for: - HDL-C - increased only in VHFLC diet - LDL-C, total-C - lowered only in LFHC diet Values reported are all unadjusted. WG SS p values NR."
"WG: N BG: N Favored LFHC diet At12 wks VHFLC diet -0.08mmol/L LFHC -0.0.33mmol/L BG SS p=0.013"
"WG: Y BG: N At12 wks VHFLC diet -0.52mmol/L LFHC -0.54mmol/L BG NSS "
"WG: NR BG: N Favored LFHC diet At 12 wks VHFLC diet +0.13mmol/L LFHC -0.96mmol/L BG SS p<0.001 "
"WG: Y BG: Y At 12 wks VHFLC diet +0.14mmol/L LFHC -0.01mmol/L BG SS p<0.001 "
"WG: N BG: N Favored LFHC diet At 12 wks VHFLC diet +0.26mmol/L LFHC -0.78mmol/L BG SS p<0.001"
"WG: Y BG: N At 12 wks VHFLC diet -0.53mmol/L LFHC -0.41mmol/L BG NSS "
"Weight, body fat%, visceral fat mass, abdominal subcutaneous fat: all WG: Y BG: N At 12 wks Weight VHFLC diet: -10.4% LFHC: -10.9% WG SS both, BG NSS Visceral fat area VHFLC diet: -28.8% LFHC: -29.4% WG SS both, BG NSS "
"WG: Y BG: N At 12 wks VHFLC diet: -14mmHg LFHC: -15mmHg BG NSS "
"WG: Y BG: N At 12 wks VHFLC diet: -2.3mmHg LFHC -8mmHg: BG NSS "
"WG: Y BG: N At 12 wks VHFLC diet: -5.70mU/L LFHC: -5.52mU/L BG NSS "
"HOMA2-IR & HOMA2-%S WG: Y BG: N HOMA2-IR At 12 wks VHFLC diet -0.48 LFHC -0.60BG NSS "
"All liver function markers improved or NSS change. "
" Our results are in line with systematic reviews and metaanalyses of epidemiologic and dietary intervention studies,which overall do not support a causal connection between SFA intake per se and risk of metabolic syndrome, fatty liver, or CVD, regardless of the effects on LDL cholesterol. ...Consuming E primarily as carbohydrate or fat for 3 mo did not differentially inﬂuence visceral fat and metabolic syndrome in a low-processed, lower-glycemic dietary context. Our data do not support the idea that dietary fat per se promotes ectopic [in abnormal place] adiposity and cardiometabolic syndrome in humans."
AHA - American Heart Association;
ALT - alanine aminotransferase;
AMDR - acceptable macronutrient distribution range;
AST - aspartate aminotransferase;
BG - between study groups;
BHOB - beta-hydroxybutyrate;
DBP - diastolic blood pressure;
E- energy, caloric intake;
eGFR - estimated glomerular filtration rate;
FBG - fasting blood glucose;
GGT - gamma-glutamyl transferase;
HDL-C - high-density lipoprotein cholesterol;
iGFR - isotope glomerurar filtration rate;
LDL-C - low-density lipoprotein cholesterol;
NAFLD - non-alcoholic fatty liver disease;
NR - not reported (or data needed for calculation not available);
N - no;
NA - not applicable;
NS - not specified;
NSS - not statistically significant;
SBP - systolic blood pressure;
SS - statistically significant;
TG - triglyceride;
total C - total cholesterol;
V - varied, mixed;
WG - within a study group;
WMD - weighted mean difference;
Y - yes
Number of People in Studies:
3,296 Enrolled in randomized controlled trials on 25% or less carbohydrates
2,626 Completed randomized controlled trials on 25% or less carbohydrates
79.67% 82% completion of studies
Duration of Trial
1 -2 years
# of Trials
Join the Low-Carb Action Network to stay informed of our latest news and calls to action.
Don't miss out on the chance to lend your voice for change!